尿路感染症治療薬の世界市場規模調査＆予測、薬剤別、適応症別、地域別分析、2022-2029年

尿路感染症治療薬の世界市場は、2021年に約86億6,000万米ドルと評価され、予測期間2022-2029年には3%以上の成長率で順調に成長すると予測されています。

尿路感染症は、男性に比べて女性に多く発生する最も一般的な細菌感染症の1つです。尿路を侵します。尿路感染症治療薬市場は、腎臓結石や糖尿病の有病率の高まりや併用薬の発売などの要因から拡大しています。

世界保健機関2019によると、糖尿病は世界で約150万人の命を奪った、糖尿病は現在、推定で世界で5億3700万人に影響を与えています。2045年には、全世界で7億8300万人の糖尿病患者が発生すると予測されています。一方、老年人口の増加や市場関係者による研究開発活動の活発化により、市場には有利な機会が生まれています。しかし、新興国では認知度が低いため、2022年から2029年の予測期間中、市場の成長を妨げる要因となっています。

尿路感染症治療薬の世界市場調査において考慮された主要地域は、アジア太平洋地域、北米、欧州、ラテンアメリカ、その他世界の地域です。北米は、腎臓結石や糖尿病の有病率の増加により、売上高で市場を独占しています。また、北米は、尿路結石に対する意識の高まり、パーソナルケアへの支出の増加、予測期間中の市場関係者の成長活動などの要因により、予測期間中に最も高いCAGRで成長すると予想されます。

最近の新興国市場の動向

• 2021年10月、Spero Therapeutics Inc.が、腎盂腎炎を含む感受性微生物別複雑性尿路感染症（cUTI）治療薬として、tebipenem HBr錠の承認を求める新薬申請（NDA）を米国食品医薬品局（FDA）に提出しました。
• 2021年9月には、インドの大手ジェネリック医薬品会社であるBDR Pharma社から、腹腔内感染症、下気道感染症、複雑性尿路感染症の患者の治療薬として、ビアペネムが発売されています。

世界の尿路感染症治療薬市場レポート範囲

• 過去データ：2019-2020-2021年
• 推計の基準年：2021年
• 予測期間：2022-2029年
• レポート範囲：収益予測、企業ランキング、競合情勢、成長要因、動向
• 地域別範囲：北米、欧州、アジア太平洋地域、ラテンアメリカ、世界のその他地域
• カスタマイズの範囲：レポートカスタマイズ（最大8名分の作業時間）を無料で提供。国別、地域別、セグメント別範囲の追加・変更。

本調査の目的は、近年における様々な分野・国の市場規模を明らかにし、今後数年間の市場規模を予測することです。本レポートは、調査対象国の産業の質的・量的な側面を取り込むよう設計されています。

また、市場の将来的な成長を規定する促進要因や課題など、重要な側面に関する詳細情報も提供しています。さらに、主要企業の競合情勢などの詳細な分析とともに、利害関係者が投資するためのミクロ市場での潜在的な機会も組み込んでいます。

目次

第1章 エグゼクティブサマリー

• マーケットスナップショット
• 世界・セグメント別市場推定・予測、2019年～2029年
  • 尿路感染症治療薬市場、地域別、2019-2029年
  • 尿路感染症治療薬市場、薬剤別、2019-2029年
  • 尿路感染症治療薬市場、適応症別、2019-2029年
• 主な動向
• 調査手法
• 調査の前提条件

第2章 尿路感染症治療薬の世界市場の定義と範囲

• 調査目的
• 市場の定義と範囲
  • 調査対象範囲
  • 産業の進化
• 本調査の対象となった年
• 通貨換算レート

第3章 尿路感染症治療薬の世界市場力学

• 尿路感染症治療薬市場のインパクト分析（2019年～2029年）
  • 市場促進要因
    • 腎臓結石や糖尿病などの有病率の増加
    • 配合剤の発売
  • 市場の課題
    • 新興国での認知度の低さ
  • 市場機会
    • 老年人口の増加
    • 市場関係者別研究開発活動の活発化

第4章 世界の尿路感染症治療薬市場の産業分析

• ポーターの5フォースモデル
  • 供給企業の交渉力
  • 買い手の交渉力
  • 新規参入業者の脅威
  • 代替品の脅威
  • 競争企業間の敵対関係
• ポーターの5フォースモデルへの未来的アプローチ（2019-2029年）
• PEST分析
  • 政治的
  • 経済的
  • ソーシャル
  • テクニカル
• 最高の投資機会
• 主要成功戦略
• 業界関係者見通し
• アナリストの提言と結論

第5章 リスクアセスメントCOVID-19の影響

• COVID-19が業界に与える全体的な影響についての評価
• COVID-19以前とCOVID-19以後の市場シナリオ

第6章 尿路感染症治療薬の世界市場：薬物別

• マーケットスナップショット
• 尿路感染症治療薬の世界市場：薬剤別、性能別-潜在能力分析
• 尿路感染症治療薬の世界市場薬剤別推定・予測2019-2029
• 尿路感染症治療薬市場、サブセグメント別分析
  • ペニシリンと併用
  • キノロン
  • セファロスポリン
  • アゾール系とアムホテリシンB
  • ニトロフラン
  • その他の医薬品尿路感染症治療薬の世界市場：適応症別マーケットスナップショット
• 尿路感染症治療薬の世界市場：適応症別、業績別- ポテンシャル分析
• 尿路感染症治療薬の世界市場、適応症別推定・予測2019-2029
• 尿路感染症治療薬市場、サブセグメント分析
  • 複雑な尿路結石症
  • 非合併型尿路結石症
  • その他の適応症

第7章 尿路感染症治療薬の世界市場：地域別分析

• 尿路感染症治療薬市場、地域別マーケットスナップショット
• 北米
  • 米国
    • 薬剤別の推定・予測、2019年～2029年
    • 適応症別の推定・予測、2019年～2029年
  • カナダ
• 欧州尿路感染症治療薬市場スナップショット
  • 英国
  • ドイツ
  • フランス
  • スペイン
  • イタリア
  • その他欧州
• アジア太平洋地域の尿路感染症治療薬市場スナップショット
  • 中国
  • インド
  • 日本
  • オーストラリア
  • 韓国
  • その他アジア太平洋地域
• ラテンアメリカ尿路感染症治療薬市場スナップショット
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ地域
• 世界のその他の地域

第8章 競合情報

• トップ市場戦略
• 企業プロファイル
  • AstraZeneca
    • 主要な情報
    • 概要
    • 財務（データの入手が可能な場合のみ）
    • 製品概要
    • 最近の動向
  • Bayer AG
  • Cipla Inc.
  • GlaxoSmithKline PLC
  • Shionogi & Co. Ltd
  • Novartis AG
  • Pfizer
  • Merck & Co. Inc
  • Bristol-Myers Squibb Company
  • Almirall SA

第9章 調査のプロセス

• 調査プロセス
  • データマイニング
  • 分析
  • 市場推定
  • バリデーション
  • 出版
• 調査の特徴
• 調査の前提条件

LIST OF TABLES

• TABLE 1. Global Urinary Tract Infection Therapeutics Market, report scope
• TABLE 2. Global Urinary Tract Infection Therapeutics Market estimates & forecasts by Region 2019-2029 (USD Billion)
• TABLE 3. Global Urinary Tract Infection Therapeutics Market estimates & forecasts by Drug 2019-2029 (USD Billion)
• TABLE 4. Global Urinary Tract Infection Therapeutics Market estimates & forecasts by Indication 2019-2029 (USD Billion)
• TABLE 5. Global Urinary Tract Infection Therapeutics Market by segment, estimates & forecasts, 2019-2029 (USD Billion)
• TABLE 6. Global Urinary Tract Infection Therapeutics Market by region, estimates & forecasts, 2019-2029 (USD Billion)
• TABLE 7. Global Urinary Tract Infection Therapeutics Market by segment, estimates & forecasts, 2019-2029 (USD Billion)
• TABLE 8. Global Urinary Tract Infection Therapeutics Market by region, estimates & forecasts, 2019-2029 (USD Billion)
• TABLE 9. Global Urinary Tract Infection Therapeutics Market by segment, estimates & forecasts, 2019-2029 (USD Billion)
• TABLE 10. Global Urinary Tract Infection Therapeutics Market by region, estimates & forecasts, 2019-2029 (USD Billion)
• TABLE 11. Global Urinary Tract Infection Therapeutics Market by segment, estimates & forecasts, 2019-2029 (USD Billion)
• TABLE 12. Global Urinary Tract Infection Therapeutics Market by region, estimates & forecasts, 2019-2029 (USD Billion)
• TABLE 13. Global Urinary Tract Infection Therapeutics Market by segment, estimates & forecasts, 2019-2029 (USD Billion)
• TABLE 14. Global Urinary Tract Infection Therapeutics Market by region, estimates & forecasts, 2019-2029 (USD Billion)
• TABLE 15. U.S. Urinary Tract Infection Therapeutics Market estimates & forecasts, 2019-2029 (USD Billion)
• TABLE 16. U.S. Urinary Tract Infection Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
• TABLE 17. U.S. Urinary Tract Infection Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
• TABLE 18. Canada Urinary Tract Infection Therapeutics Market estimates & forecasts, 2019-2029 (USD Billion)
• TABLE 19. Canada Urinary Tract Infection Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
• TABLE 20. Canada Urinary Tract Infection Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
• TABLE 21. UK Urinary Tract Infection Therapeutics Market estimates & forecasts, 2019-2029 (USD Billion)
• TABLE 22. UK Urinary Tract Infection Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
• TABLE 23. UK Urinary Tract Infection Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
• TABLE 24. Germany Urinary Tract Infection Therapeutics Market estimates & forecasts, 2019-2029 (USD Billion)
• TABLE 25. Germany Urinary Tract Infection Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
• TABLE 26. Germany Urinary Tract Infection Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
• TABLE 27. France Urinary Tract Infection Therapeutics Market estimates & forecasts, 2019-2029 (USD Billion)
• TABLE 28. France Urinary Tract Infection Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
• TABLE 29. France Urinary Tract Infection Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
• TABLE 30. Italy Urinary Tract Infection Therapeutics Market estimates & forecasts, 2019-2029 (USD Billion)
• TABLE 31. Italy Urinary Tract Infection Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
• TABLE 32. Italy Urinary Tract Infection Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
• TABLE 33. Spain Urinary Tract Infection Therapeutics Market estimates & forecasts, 2019-2029 (USD Billion)
• TABLE 34. Spain Urinary Tract Infection Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
• TABLE 35. Spain Urinary Tract Infection Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
• TABLE 36. RoE Urinary Tract Infection Therapeutics Market estimates & forecasts, 2019-2029 (USD Billion)
• TABLE 37. RoE Urinary Tract Infection Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
• TABLE 38. RoE Urinary Tract Infection Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
• TABLE 39. China Urinary Tract Infection Therapeutics Market estimates & forecasts, 2019-2029 (USD Billion)
• TABLE 40. China Urinary Tract Infection Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
• TABLE 41. China Urinary Tract Infection Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
• TABLE 42. India Urinary Tract Infection Therapeutics Market estimates & forecasts, 2019-2029 (USD Billion)
• TABLE 43. India Urinary Tract Infection Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
• TABLE 44. India Urinary Tract Infection Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
• TABLE 45. Japan Urinary Tract Infection Therapeutics Market estimates & forecasts, 2019-2029 (USD Billion)
• TABLE 46. Japan Urinary Tract Infection Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
• TABLE 47. Japan Urinary Tract Infection Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
• TABLE 48. South Korea Urinary Tract Infection Therapeutics Market estimates & forecasts, 2019-2029 (USD Billion)
• TABLE 49. South Korea Urinary Tract Infection Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
• TABLE 50. South Korea Urinary Tract Infection Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
• TABLE 51. Australia Urinary Tract Infection Therapeutics Market estimates & forecasts, 2019-2029 (USD Billion)
• TABLE 52. Australia Urinary Tract Infection Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
• TABLE 53. Australia Urinary Tract Infection Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
• TABLE 54. RoAPAC Urinary Tract Infection Therapeutics Market estimates & forecasts, 2019-2029 (USD Billion)
• TABLE 55. RoAPAC Urinary Tract Infection Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
• TABLE 56. RoAPAC Urinary Tract Infection Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
• TABLE 57. Brazil Urinary Tract Infection Therapeutics Market estimates & forecasts, 2019-2029 (USD Billion)
• TABLE 58. Brazil Urinary Tract Infection Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
• TABLE 59. Brazil Urinary Tract Infection Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
• TABLE 60. Mexico Urinary Tract Infection Therapeutics Market estimates & forecasts, 2019-2029 (USD Billion)
• TABLE 61. Mexico Urinary Tract Infection Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
• TABLE 62. Mexico Urinary Tract Infection Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
• TABLE 63. RoLA Urinary Tract Infection Therapeutics Market estimates & forecasts, 2019-2029 (USD Billion)
• TABLE 64. RoLA Urinary Tract Infection Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
• TABLE 65. RoLA Urinary Tract Infection Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
• TABLE 66. Row Urinary Tract Infection Therapeutics Market estimates & forecasts, 2019-2029 (USD Billion)
• TABLE 67. Row Urinary Tract Infection Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
• TABLE 68. Row Urinary Tract Infection Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
• TABLE 69. List of secondary sources, used in the study of global Urinary Tract Infection Therapeutics Market
• TABLE 70. List of primary sources, used in the study of global Urinary Tract Infection Therapeutics Market
• TABLE 71. Years considered for the study
• TABLE 72. Exchange rates considered

List of tables and figures and dummy in nature, final lists may vary in the final deliverable

LIST OF FIGURES

List of figures

• FIG 1. Global Urinary Tract Infection Therapeutics Market, research methodology
• FIG 2. Global Urinary Tract Infection Therapeutics Market, Market estimation techniques
• FIG 3. Global Market size estimates & forecast methods
• FIG 4. Global Urinary Tract Infection Therapeutics Market, key trends 2021
• FIG 5. Global Urinary Tract Infection Therapeutics Market, growth prospects 2022-2029
• FIG 6. Global Urinary Tract Infection Therapeutics Market, porters 5 force model
• FIG 7. Global Urinary Tract Infection Therapeutics Market, pest analysis
• FIG 8. Global Urinary Tract Infection Therapeutics Market, value chain analysis
• FIG 9. Global Urinary Tract Infection Therapeutics Market by segment, 2019 & 2029 (USD Billion)
• FIG 10. Global Urinary Tract Infection Therapeutics Market by segment, 2019 & 2029 (USD Billion)
• FIG 11. Global Urinary Tract Infection Therapeutics Market by segment, 2019 & 2029 (USD Billion)
• FIG 12. Global Urinary Tract Infection Therapeutics Market by segment, 2019 & 2029 (USD Billion)
• FIG 13. Global Urinary Tract Infection Therapeutics Market by segment, 2019 & 2029 (USD Billion)
• FIG 14. Global Urinary Tract Infection Therapeutics Market, regional snapshot 2019 & 2029
• FIG 15. North America Urinary Tract Infection Therapeutics Market 2019 & 2029 (USD Billion)
• FIG 16. Europe Urinary Tract Infection Therapeutics Market 2019 & 2029 (USD Billion)
• FIG 17. Asia Pacific Urinary Tract Infection Therapeutics Market 2019 & 2029 (USD Billion)
• FIG 18. Latin America Urinary Tract Infection Therapeutics Market 2019 & 2029 (USD Billion)
• FIG 19. Global Urinary Tract Infection Therapeutics Market, company Market share analysis (2021)

List of tables and figures and dummy in nature, final lists may vary in the final deliverable

The global Urinary Tract Infection Therapeutics Market is valued at approximately USD 8.66 billion in 2021 and is anticipated to grow with a healthy growth rate of more than 3 % over the forecast period 2022-2029. Urinary Tract Infection is one of the most common bacterial infections that occur majorly in women as compared to men. It affects the urinary tract. The Urinary Tract Infection Therapeutics market is expanding because of factors such as the rising growing prevalence of kidney stones and diabetes and the launch of combination drugs.

According to the World Health Organization 2019, diabetes claimed the lives of approximately 1.5 million people worldwide, Diabetes currently affects 537 million people worldwide, according to estimates. Projections show that by 2045, there will be 783 million diabetics worldwide. Whereas the rising geriatric population and growing R&D activities by market players create lucrative opportunities for the market. However, lack of awareness in developing countries hampers market growth throughout the forecast period of 2022-2029.

The key regions considered for the Global Urinary Tract Infection Therapeutics Market study include Asia Pacific, North America, Europe, Latin America, and the Rest of the World. North America dominated the market in terms of revenue, owing to the increasing prevalence of kidney stones, and diabetes. , Also, North America is expected to grow with the highest CAGR during the forecast period, owing to factors such as increasing awareness towards UTIs, growing spending towards personal care, and growth activities by market players in the forecast period.

Major market players included in this report are:

• AstraZeneca
• Bayer AG
• Cipla Inc.
• GlaxoSmithKline PLC
• Shionogi & Co. Ltd
• Novartis AG
• Pfizer
• Merck & Co. Inc
• Bristol-Myers Squibb Company
• Almirall SA

Recent Developments in the Market:

• In October 2021, Spero Therapeutics Inc. submitted a new drug application (NDA) to the US Food and Drug Administration (FDA) seeking approval for tebipenem HBr tablets for the treatment of complicated urinary tract infections (cUTI) caused by susceptible microorganisms, including pyelonephritis.
• In September 2021, Biapenem was introduced by BDR Pharma, one of India's leading generic pharmaceutical companies, to treat patients with intra-abdominal infections, lower respiratory infections, or complicated urinary tract infections.

Global Urinary Tract Infection Therapeutics Market Report Scope:

• Historical Data: 2019-2020-2021

• Base Year for Estimation: 2021

• Forecast period: 2022-2029

• Report Coverage: Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends

• Segments Covered: Drug, Indication, Region

• Regional Scope: North America; Europe; Asia Pacific; Latin America; Rest of the World

• Customization Scope: Free report customization (equivalent up to 8 analyst's working hours) with purchase. Addition or alteration to country, regional & segment scope*

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:

By Drug:

• Penicillin and Combinations
• Quinolones
• Cephalosporin
• Azoles and Amphotericin B
• Nitrofurans
• Other Drugs

By Indication:

• Complicated UTI
• Uncomplicated UTI
• Other Indications

By Region:

• North America
• U.S.
• Canada
• Europe
• UK
• Germany
• France
• Spain
• Italy
• ROE
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• RoAPAC
• Latin America
• Brazil
• Mexico
• RoLA
• Rest of the World

Table of Contents

Chapter 1. Executive Summary

• 1.1. Market Snapshot
• 1.2. Global & Segmental Market Estimates & Forecasts, 2019-2029 (USD Billion)
  • 1.2.1. Urinary Tract Infection Therapeutics Market, by Region, 2019-2029 (USD Billion)
  • 1.2.2. Urinary Tract Infection Therapeutics Market, by Drug, 2019-2029 (USD Billion)
  • 1.2.3. Urinary Tract Infection Therapeutics Market, by Indication, 2019-2029 (USD Billion)
• 1.3. Key Trends
• 1.4. Estimation Methodology
• 1.5. Research Assumption

Chapter 2. Global Urinary Tract Infection Therapeutics Market Definition and Scope

• 2.1. Objective of the Study
• 2.2. Market Definition & Scope
  • 2.2.1. Scope of the Study
  • 2.2.2. Industry Evolution
• 2.3. Years Considered for the Study
• 2.4. Currency Conversion Rates

Chapter 3. Global Urinary Tract Infection Therapeutics Market Dynamics

• 3.1. Urinary Tract Infection Therapeutics Market Impact Analysis (2019-2029)
  • 3.1.1. Market Drivers
    • 3.1.1.1. Growing prevalence of kidney stones and diabetes
    • 3.1.1.2. Launch of combination drugs
  • 3.1.2. Market Challenges
    • 3.1.2.1. Lack of awareness in developing countries
  • 3.1.3. Market Opportunities
    • 3.1.3.1. Rising geriatric population
    • 3.1.3.2. Growing R&D activities by market players

Chapter 4. Global Urinary Tract Infection Therapeutics Market Industry Analysis

• 4.1. Porter's 5 Force Model
  • 4.1.1. Bargaining Power of Suppliers
  • 4.1.2. Bargaining Power of Buyers
  • 4.1.3. Threat of New Entrants
  • 4.1.4. Threat of Substitutes
  • 4.1.5. Competitive Rivalry
• 4.2. Futuristic Approach to Porter's 5 Force Model (2019-2029)
• 4.3. PEST Analysis
  • 4.3.1. Political
  • 4.3.2. Economical
  • 4.3.3. Social
  • 4.3.4. Technological
• 4.4. Top investment opportunity
• 4.5. Top winning strategies
• 4.6. Industry Experts Prospective
• 4.7. Analyst Recommendation & Conclusion

Chapter 5. Risk Assessment: COVID-19 Impact

• 5.1. Assessment of the overall impact of COVID-19 on the industry
• 5.2. Pre COVID-19 and post COVID-19 Market scenario

Chapter 6. Global Urinary Tract Infection Therapeutics Market, by Drug

• 6.1. Market Snapshot
• 6.2. Global Urinary Tract Infection Therapeutics Market by Drug, Performance - Potential Analysis
• 6.3. Global Urinary Tract Infection Therapeutics Market Estimates & Forecasts by Drug 2019-2029 (USD Billion)
• 6.4. Urinary Tract Infection Therapeutics Market, Sub-Segment Analysis
  • 6.4.1. Penicillin and Combinations
  • 6.4.2. Quinolones
  • 6.4.3. Cephalosporin
  • 6.4.4. Azoles and Amphotericin B
  • 6.4.5. Nitrofurans
  • 6.4.6. Other Drugs Global Urinary Tract Infection Therapeutics Market, by Indication Market Snapshot
• 6.5. Global Urinary Tract Infection Therapeutics Market by Indication, Performance - Potential Analysis
• 6.6. Global Urinary Tract Infection Therapeutics Market Estimates & Forecasts by Indication 2019-2029 (USD Billion)
• 6.7. Urinary Tract Infection Therapeutics Market, Sub Segment Analysis
  • 6.7.1. Complicated UTI
  • 6.7.2. Uncomplicated UTI
  • 6.7.3. Other Indications

Chapter 7. Global Urinary Tract Infection Therapeutics Market, Regional Analysis

• 7.1. Urinary Tract Infection Therapeutics Market, Regional Market Snapshot
• 7.2. North America Urinary Tract Infection Therapeutics Market
  • 7.2.1. U.S. Urinary Tract Infection Therapeutics Market
    • 7.2.1.1. Drug breakdown estimates & forecasts, 2019-2029
    • 7.2.1.2. Indication breakdown estimates & forecasts, 2019-2029
  • 7.2.2. Canada Urinary Tract Infection Therapeutics Market
• 7.3. Europe Urinary Tract Infection Therapeutics Market Snapshot
  • 7.3.1. U.K. Urinary Tract Infection Therapeutics Market
  • 7.3.2. Germany Urinary Tract Infection Therapeutics Market
  • 7.3.3. France Urinary Tract Infection Therapeutics Market
  • 7.3.4. Spain Urinary Tract Infection Therapeutics Market
  • 7.3.5. Italy Urinary Tract Infection Therapeutics Market
  • 7.3.6. Rest of Europe Urinary Tract Infection Therapeutics Market
• 7.4. Asia-Pacific Urinary Tract Infection Therapeutics Market Snapshot
  • 7.4.1. China Urinary Tract Infection Therapeutics Market
  • 7.4.2. India Urinary Tract Infection Therapeutics Market
  • 7.4.3. Japan Urinary Tract Infection Therapeutics Market
  • 7.4.4. Australia Urinary Tract Infection Therapeutics Market
  • 7.4.5. South Korea Urinary Tract Infection Therapeutics Market
  • 7.4.6. Rest of Asia Pacific Urinary Tract Infection Therapeutics Market
• 7.5. Latin America Urinary Tract Infection Therapeutics Market Snapshot
  • 7.5.1. Brazil Urinary Tract Infection Therapeutics Market
  • 7.5.2. Mexico Urinary Tract Infection Therapeutics Market
  • 7.5.3. Rest of Latin America Urinary Tract Infection Therapeutics Market
• 7.6. Rest of The World Urinary Tract Infection Therapeutics Market

Chapter 8. Competitive Intelligence

• 8.1. Top Market Strategies
• 8.2. Company Profiles
  • 8.2.1. AstraZeneca
    • 8.2.1.1. Key Information
    • 8.2.1.2. Overview
    • 8.2.1.3. Financial (Subject to Data Availability)
    • 8.2.1.4. Product Summary
    • 8.2.1.5. Recent Developments
  • 8.2.2. Bayer AG
  • 8.2.3. Cipla Inc.
  • 8.2.4. GlaxoSmithKline PLC
  • 8.2.5. Shionogi & Co. Ltd
  • 8.2.6. Novartis AG
  • 8.2.7. Pfizer
  • 8.2.8. Merck & Co. Inc
  • 8.2.9. Bristol-Myers Squibb Company
  • 8.2.10. Almirall SA

Chapter 9. Research Process

• 9.1. Research Process
  • 9.1.1. Data Mining
  • 9.1.2. Analysis
  • 9.1.3. Market Estimation
  • 9.1.4. Validation
  • 9.1.5. Publishing
• 9.2. Research Attributes
• 9.3. Research Assumption